Natixis Advisors LLC Makes New Investment in Medline $MDLN

Natixis Advisors LLC acquired a new position in Medline (NASDAQ:MDLN) during the fourth quarter, HoldingsChannel reports. The fund acquired 111,089 shares of the company’s stock, valued at approximately $4,666,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mass General Brigham Inc acquired a new position in Medline in the fourth quarter worth $1,104,000. Baillie Gifford & Co. acquired a new position in Medline in the fourth quarter worth $437,236,000. Massachusetts Financial Services Co. MA acquired a new position in Medline in the fourth quarter worth $429,544,000. UBS Group AG acquired a new position in Medline in the fourth quarter worth $54,707,000. Finally, Pictet Asset Management Holding SA acquired a new position in Medline in the fourth quarter worth $48,996,000.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Barclays reduced their price objective on Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft set a $42.00 price target on Medline in a research note on Thursday, May 7th. Citigroup cut their price target on Medline from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Robert W. Baird cut their price target on Medline from $57.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 3rd. Finally, Sanford C. Bernstein cut their price target on Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.54.

Medline Price Performance

NASDAQ:MDLN opened at $33.80 on Tuesday. Medline has a 1-year low of $32.81 and a 1-year high of $50.88. The firm has a 50-day moving average of $41.29. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65.

Medline (NASDAQ:MDLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.04. The business had revenue of $7.35 billion during the quarter. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. Analysts predict that Medline will post 1.51 earnings per share for the current year.

Medline Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.